Leslie WalkerHumira, the injectable biologic treatment for rheumatoid arthritis, now faces its first competition from one of several copycat "biosimilar" drugs expected to come to market this year. "A fierce fight for market shareIn order to pass this test — and demonstrate biosimilars can have a strong, healthy future in the U. They could change regulations, and try to make the market a cheaper, easier place for companies to thrive